Tag Archives: cell lung cancer

Henrietta Lacks: At Your Cervix

This video should go ‘viral’. Every woman in the world should view this.

Vaccines are biological weapons.  Do not submit to be killed by them.  Stay the F$$$ out from them and if you are near them call Homeland Security and the EPA for a biohazard cleanup.

All other videos on the topic of Henrietta Lacks make it appear as if her cancerous cervical cells are the greatest thing for medicine and humanity in general, and while i understand, from a research perspective, how beneficial cells like this would be. i am curious how anyone “benefits” from receiving cancer cells that never die in vaccines. Since we have had vaccines, cancer deaths have skyrocketed, as well as autism, diabetes and a slue of other debilitating diseases.

Source:

vaccinefraud

 Patrick Jordan @ http://www.VaccineFraud.com

 

Fair Use Notice: Images/logos/graphics on this page contains some copyrighted material whose use has not been authorized by the copyright owners. We believe that this not-for-profit, educational, and/or criticism or commentary use on the Web constitutes a fair use of the copyrighted material (as provided for in section 107 of the US Copyright Law).

Drug Information Update- FDA approves new pill to treat certain patients with non-small cell lung cancer

Drug Information Update- FDA approves new pill to treat certain patients with non-small cell lung cancer
FDA Division of Drug Information: Know the Moment It Happens

The Division of Drug Information (DDI) is CDER’s focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.

Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

Today, the FDA also approved the first companion diagnostic test (cobas EGFR Mutation Test v2) to detect the type of EGFR resistance mutation that Tagrisso is known to target. The newly approved version (v2) of the test adds the T790M mutation to the clinically relevant mutations detected by the original cobas EGFR Mutation Test (v1).

The most common side effects of Tagrisso are diarrhea, skin and nail conditions such as dry skin, rash and infection or redness around the fingernails. Tagrisso may cause serious side effects, including inflammation of the lungs and injury to the heart. It also may cause harm to a developing fetus.

The FDA granted Astra Zeneca breakthrough therapy designation, priority review and orphan drug designation for Tagrisso. Breakthrough therapy designation is granted for a drug that is intended to treat a serious condition when, at the time an application is submitted, preliminary clinical evidence indicates that a drug may demonstrate substantial improvement over available therapies. Priority review
designation is granted to drug applications that show a significant improvement in safety or effectiveness in the treatment of a serious condition. Orphan drug designation
provides incentives such as tax credits, user fee waivers, and eligibility for market exclusivity to assist and encourage the development of drugs for rare diseases.

Tagrisso was approved under the agency’s accelerated approval program which allows the approval of a drug to treat a serious or
life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. This program provides earlier patient access to promising new drugs while the company conducts confirmatory clinical trials.

For more information please visit: Tagrisso